Melanoma
55 programs · 55 companies
Programs
55
Companies
55
Trials
69
MOAs
35
IL-13iVEGFiSHP2iGLP-1agMDM2iAuroraAiAHRantSTINGagCDK4/6iPI3Ki
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-8902 | Preclinical | TROP-2 | ||
| Capifutibatinib | Phase 3 | GIP-R | ||
| Talatapinarof | Phase 1/2 | PCSK9 | ||
| CRS-184 | Phase 1/2 | AHR | ||
| ZEA-9089 | Phase 2/3 | Menin | ||
| SND-9531 | Phase 3 | TYK2 | ||
| Liraratamab | Phase 3 | SGLT2 | ||
| Rimainavolisib | Phase 3 | TYK2 | ||
| 992-9448 | Preclinical | GPRC5D | ||
| PHA-4842 | Approved | BTK | ||
| UCL-IIT-649 | NDA/BLA | PLK4 | ||
| AER-1540 | Phase 2/3 | TIM-3 | ||
| CGE-1556 | Phase 1 | KRASG12C | ||
| Lirasacituzumab | Preclinical | PCSK9 | ||
| Lisotapinarof | Approved | IL-17A | ||
| INH-5545 | Phase 3 | CD19 | ||
| CN-9071 | Preclinical | WRN | ||
| Zanufotisoran | Phase 1/2 | ALK | ||
| CLR-3690 | Phase 3 | RET | ||
| SEC-7279 | Phase 2 | IL-13 | ||
| ELI-3182 | Preclinical | PLK4 | ||
| Voxasertib | Phase 3 | MDM2 | ||
| Tixazasiran | Phase 1 | MET | ||
| KUM-1252 | Preclinical | Tau | ||
| Talafotisoran | Phase 1 | USP1 | ||
| LAE-436 | Preclinical | MET | ||
| Nirasacituzumab | Phase 3 | EGFR | ||
| ASK-5918 | Phase 2/3 | GLP-1R | ||
| TER-1034 | Phase 3 | FGFR | ||
| CAP-2067 | Phase 2/3 | JAK2 | ||
| Lisosotorasib | Phase 3 | CFTR | ||
| MAS-IIT-645 | Phase 1 | MET | ||
| Sovazumab | Phase 1 | IL-13 | ||
| ASK-1666 | Approved | CD38 | ||
| GEN-IIT-770 | Phase 1 | TIM-3 | ||
| Rilunaritide | Phase 2 | EZH2 | ||
| PMV-3715 | Phase 2/3 | TNFα | ||
| RNA-7525 | Phase 2/3 | TYK2 | ||
| Mavutenlimab | Phase 2 | EGFR | ||
| CAL-5800 | Phase 1/2 | GLP-1R | ||
| Datorapivir | Phase 1 | SMN2 | ||
| Doxazasiran | Phase 2/3 | PLK4 | ||
| Rimasotorasib | Phase 1/2 | WRN | ||
| VBI-124 | Phase 2/3 | FGFR | ||
| IDI-2657 | Approved | FGFR | ||
| Lisovorutinib | Phase 2/3 | BET | ||
| SUV-4226 | Phase 3 | AHR | ||
| ZYD-7355 | Phase 1 | VEGF | ||
| EMS-5854 | Phase 2 | KRASG12C | ||
| Teralucimab | Phase 1 | CD19 | ||
| RGE-5524 | Phase 1 | RET | ||
| Adagraosocimab | Approved | PARP | ||
| Sotovorutinib | Phase 1/2 | AuroraA | ||
| Gelirasimod | NDA/BLA | CD38 | ||
| 299-6118 | Phase 1/2 | MET |
Trials (69)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08314519 | NVS-8902 | Preclinical | Recruiting |
| NCT03224728 | NVS-8902 | Preclinical | Not yet recr... |
| NCT07543876 | Capifutibatinib | Phase 3 | Recruiting |
| NCT06957021 | Talatapinarof | Phase 1/2 | Active |
| NCT05498109 | ZEA-9089 | Phase 2/3 | Completed |
| NCT07932939 | ZEA-9089 | Phase 2/3 | Recruiting |
| NCT07090804 | SND-9531 | Phase 3 | Not yet recr... |
| NCT07902060 | SND-9531 | Phase 3 | Not yet recr... |
| NCT08934250 | Rimainavolisib | Phase 3 | Active |
| NCT04933213 | PHA-4842 | Approved | Completed |
| NCT06203371 | UCL-IIT-649 | NDA/BLA | Not yet recr... |
| NCT05252502 | AER-1540 | Phase 2/3 | Recruiting |
| NCT07646617 | Lirasacituzumab | Preclinical | Terminated |
| NCT08054158 | Lisotapinarof | Approved | Recruiting |
| NCT08429386 | Lisotapinarof | Approved | Completed |
| NCT07468733 | Lisotapinarof | Approved | Recruiting |
| NCT06233511 | INH-5545 | Phase 3 | Active |
| NCT05967588 | INH-5545 | Phase 3 | Recruiting |
| NCT05549733 | CN-9071 | Preclinical | Terminated |
| NCT06829096 | Zanufotisoran | Phase 1/2 | Terminated |